干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现


共找到11条结果
排序:

简介: “基因编辑婴儿事件发生后,国际学术界非常关注,美国科学院、英国皇家学会等单位共同发起了关于该事件的大讨论,并邀请了中国科学院参加,国际科学界对一些问题形成了共识。”9日,全国人大代表、中国科学院院长、党组书记白春礼说,共识包括:就目前而言,在技术不成熟、相应的社会伦理问题未得到充分讨论解决之前,我们应当禁止对于人生殖系基因编辑的临床试验和应用;而对于基础性研究则可以允许科学家尝试探索,否则会影响科技创新的步伐。白春礼认为,生物技术立法应当顺应新兴生产力发展的需求,为生物技术发展保驾护航。“法律的制定要在科学规范、避免误用滥用和鼓励科研探索之间掌握好‘度’,不能‘因噎废食’。”严禁反人类的误用、滥用“除了基因编辑技术,还有辅助生殖技术、克隆技术、器官再造技术等,都对传统的生命伦理观提出了挑战。”白春礼说,无节制地应用,可能会引发生命随机选择、代际混乱、器官商业化、基因歧视等问题。白春礼将此类利用定义为:不法研究对生物技术的反人类利用,任其发展将有可能侵害至高无上的人性尊严和生命价值。“不允许以生殖为目的对人类胚胎或者受精卵进行基因编辑是业界共识,但仅仅靠伦理道德、自我约束会出现有意逃避监
简介: A stem cell treatment for spinal cord injuries will soon be available in Japan. Credit: Steven Needell/SPLJapan has approved a stem-cell treatment for spinal-cord injuries. The event marks the first such therapy for this kind of injury to receive government approval for sale to patients.“This is an unprecedented revolution of science and medicine, which will open a new era of healthcare,” says oncologist Masanori Fukushima, head of the Translational Research Informatics Center, a Japanese govern
简介: Marieke Essers and Theodore Alexandrov have received Chica and Heinz Schaller Award for basic biomedical researchPhoto: Rothe Chica und Heinz Schaller Award for basic biomedical research: Dr Marieke Essers (second from right) and Dr Theodore Alexandrov (centre) receiving the award. The award was handed over by the foundation’s Chairperson, Prof. Dr Rohini Kuner (second from left), Board member Prof. Dr Karoly Nikolich (left) und Prof. Dr Hans-Georg Kräusslich (right), Chairperson of the Scientif
简介: A great success for one of DKFZ’s young staff members: 22-year old Franziska Pilz came second in the Helmholtz Apprentice Award. The jury commended her for her “significant contribution to the further development of stem cell research and for her independent, proactive and responsible work”. Franziska Pilz who is currently training to be a biology laboratory assistant, worked on a project on the stem cell niche. She accepted her award on April 7.“I’m really delighted and also a little bit proud”
简介: 06 December 2017The European Health Catapult Competition reached its climax on 5 December at the EIT Health Summit in London, where a jury of experts announced the winning start-ups in the Medtech, Biotech and Digital Health categories.MedtechFollowing a year of training and competition, the top 21 of the original 42 start-ups that were accepted for the prograrmme competed for cash awards and the attention of potential investors at the EIT Health Summit in the European Health Catapult finals. Th
简介: Heidelberg, 17.05.2018BioRN Lounge: Prof. Steffen Rupp from Fraunhofer IGB talked about: ”Innate Immunity in 3D-Infection models: From simple Screening Systems to complex Immune Cell supplemented Skin Models”Once again, the BioRN Lounge was the occasion for the life science companies as well for scientists from our research institutes, to meet and chat about latest news and achievements. The BioRN Lounge is the prime monthly networking event for BioRN members. It is the occasion for exchange, me
简介: Every day, stem cells in our bone marrow produce billions of new red blood cells. Any disruption in this process can result in serious disease. Researchers from Charité -- Universitätsmedizin Berlin and Harvard Medical School have succeeded in furthering our understanding of how blood cells are formed. Their insights into the molecular foundations of this process may help break new ground in the treatment of certain types of anemia. The results of this study have been published in Cell.Thanks to
简介: BioMed X announced today the initiation of a new research collaboration with F. Hoffmann-La Roche Ltd in the field of immunology. Within the framework of the agreement, BioMed X will launch a global call for applications to establish a new biomedical research group in Heidelberg. The main objective of the new group will be to develop novel approaches for the treatment of several immune-mediated diseases.Myeloid cells are capable of dynamically exerting diverse functions in the immune system, as
简介: Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSCLCApproval based on phase III ALEX data showing Alecensa reduced the risk of disease progression or death by more than half versus crizotinibRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted a marketing authorisation for Alecensa® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced
发布时间